Arbutus Biopharma Corp last reported quarterly results on Aug 12, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $1.0 million (-90.6% year over year) and diluted EPS of -$0.03. It usually reports 37–44 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 12, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 13, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 37–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 12, 2026
43 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
1
-90.6%
|
-5
-303.8%
|
-0.03
-400.0%
|
|
May 13, 2026
43 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
179
+10054.5%
|
170
+791.9%
|
0.87
+769.2%
|
|
Nov 13, 2025
44 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
1
-60.5%
|
-8
+60.7%
|
-0.04
+60.0%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
11
+522.2%
|
3
+112.7%
|
0.01
+109.1%
|
|
May 14, 2025
44 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
2
+15.1%
|
-25
-37.2%
|
-0.13
-30.0%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
2
-26.6%
|
-13
+35.1%
|
-0.07
+42.3%
|
|
Nov 6, 2024
37 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
1
-71.3%
|
-20
+1.9%
|
-0.10
+16.7%
|
|
Aug 1, 2024
32 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABUS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Warminster, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1447028
- Former names
- TEKMIRA PHARMACEUTICALS CORP (until Aug 3, 2015); TEKMIRA PHARMACEUTICALS Corp (until Aug 3, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.